|
🐜
|
The Role of Angiogenesis in Hepatocellular Carcinoma
7 auth.
M. Morse,
Weijing Sun,
R. Kim,
A. He,
P. Abada,
M. Mynderse,
...
R. Finn
|
8 |
2018 |
8
🐜
|
|
🦁
|
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
11 auth.
R. Kim,
V. Chung,
O. Alese,
B. El-Rayes,
Daneng Li,
T. Al-Toubah,
...
M. Schell,
Jun-min Zhou,
A. Mahipal,
B. Kim,
Dae Won Kim
|
8 |
2020 |
8
🦁
|
|
🐢
|
Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.
Dae Won Kim,
Chetasi Talati,
R. Kim
|
8 |
2017 |
8
🐢
|
|
🐜
|
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
18 auth.
A. A. Abdul Razak,
M. Mau-Soerensen,
N. Gabrail,
J. Gerecitano,
A. Shields,
T. Unger,
J. Saint-Martin,
R. Carlson,
Y. Landesman,
D. McCauley,
...
T. Rashal,
U. Lassen,
R. Kim,
Lee-Anne Stayner,
M. Mirza,
M. Kauffman,
S. Shacham,
A. Mahipal
|
7 |
2016 |
7
🐜
|
|
🐜
|
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
16 auth.
Yoon-Koo Kang,
T. Yau,
J. Park,
H. Lim,
T-Y Lee,
S. Obi,
S. Chan,
S. Qin,
R. Kim,
M. Casey,
...
Connie Chen,
H. Bhattacharyya,
J. A. Williams,
O. Valota,
D. Chakrabarti,
M. Kudo
|
6 |
2015 |
6
🐜
|
|
🦁
|
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.
35 auth.
R. Kim,
D. Sarker,
T. Meyer,
T. Yau,
T. Macarulla,
Joong-Won Park,
S. Choo,
A. Hollebecque,
M. Sung,
Ho Yeong Lim,
V. Mazzaferro,
J. Trojan,
A. Zhu,
Jung‐Hwan Yoon,
Sunil Sharma,
...
Zhong‐Zhe Lin,
S. Chan,
S. Faivre,
L. Feun,
C. Yen,
J. Dufour,
D. Palmer,
J. Llovet,
Melissa Manoogian,
M. Tugnait,
Nicolas Stransky,
M. Hagel,
N. Kohl,
C. Lengauer,
C. Sherwin,
O. Schmidt-Kittler,
K. Hoeflich,
Hongliang Shi,
B. Wolf,
Yoon-Koo Kang
|
6 |
2019 |
6
🦁
|
|
🐜
|
Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
20 auth.
A. Gangi,
Jehan L Shah,
N. Hatfield,
Johnna Smith,
J. Sweeney,
Junsung Choi,
G. El-Haddad,
B. Biebel,
N. Parikh,
B. Arslan,
...
S. Hoffe,
J. Frakes,
G. Springett,
D. Anaya,
M. Malafa,
Dung-tsa Chen,
Yunyu Chen,
R. Kim,
R. Shridhar,
B. Kis
|
6 |
2018 |
6
🐜
|
|
🐜
|
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
11 auth.
T. Bekaii-Saab,
R. Kim,
Tae Won Kim,
J. O'Connor,
J. Strickler,
D. Malka,
...
A. Sartore-Bianchi,
F. Bi,
K. Yamaguchi,
T. Yoshino,
G. Prager
|
6 |
2019 |
6
🐜
|
|
🐢
|
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.
A. Mahipal,
S. Tella,
Anuhya Kommalapati,
D. Anaya,
R. Kim
|
6 |
2019 |
6
🐢
|
|
🐜
|
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
19 auth.
Megan A. Hatlen,
O. Schmidt-Kittler,
C. Sherwin,
E. Rozsahegyi,
Nooreen T. Rubin,
M. Sheets,
Joseph L. Kim,
Chandrasekhar V. Miduturu,
Neil Bifulco,
N. Brooijmans,
...
Hongliang Shi,
T. Guzi,
A. Boral,
C. Lengauer,
M. Dorsch,
R. Kim,
Yoon-Koo Kang,
B. Wolf,
K. Hoeflich
|
6 |
2019 |
6
🐜
|
